Psychoactives
June 8, 2026
Fizza Mitter, Anton Sheptooha, Janni Leung et al.
Post-traumatic stress disorder (PTSD) remains inadequately treated by existing pharmacological and psychological interventions, prompting growing interest in psychedelic-assisted psychotherapy. Although randomised controlled trials have evaluated several psychedelic agents for PTSD, to our knowledge, no prior PTSD-specific synthesis has quantitatively examined multiple agent classes within a...
BJPsych Open
June 1, 2026
Jessie Muchoki
Aims: REM sleep behaviour disorder (RBD) is characterised by loss of physiological REM atonia, resulting in dream-enactment behaviours that may be violent and pose significant risk to patients and bed partners. RBD may be idiopathic, secondary to neurological disease, or medication-induced. Medications, including antidepressants and sedative-hypnotics, have been implicated in precipitating or...
European Psychiatry
June 1, 2026
A. Kuzma-Hunt, Z. Hamadeh, V. Tsang
Introduction Ketamine-assisted therapy shows rapid benefit in treatment-resistant depression, anxiety, and PTSD (Walsh et al. BJPsych Open 2022;8:e19). The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a unique 12-week program that combines 12 Community of Practice (group therapy) sessions and three ketamine medicine sessions (Tsang et al. Ther Adv Psychopharmacol...
European Psychiatry
June 1, 2026
N. Northover, S. Kolloju, N. Ibrahim et al.
Introduction Aphantasia, the inability to voluntarily generate mental visual images, may influence emotional processing and memory encoding. While its effects on memory and cognition have been studied, its role in traumatic memory and PTSD remains underexplored. Understanding how aphantasia interacts with PTSD, depression, and social phobia is crucial, underscoring the need for further...
European Psychiatry
June 1, 2026
W. Aldulaimy, A. Shah
Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...
Molecular Psychiatry
June 1, 2026
Xin Yi, Yuan-Bo Zhang, Tong-Zhou Yu et al.
Post-traumatic stress disorder (PTSD) persists when stress biases memory systems-broadening threat engrams, weakening context-appropriate inhibition, and rendering extinction fragile. Integrating preclinical and human evidence, we argue that these liabilities are tractable within a circuit-informed framework that aligns behavioral procedures with the biology of fear memory. Extinction can be...
Public health challenges
June 1, 2026
Alishba Javaid, Rabi Jan, Afifa Khan et al.
Sleep paralysis (SP) is a parasomnia disorder connected to being unable to move your body though the experiencing person remains conscious. Factors involving this disorder are stress, post-traumatic stress disorder (PTSD), lifestyle factors including the amount of sleep, and the amount of caffeine consumed. Our study aim is to assess the symptoms, duration, time of occurrence, and body position...
Journal of trauma and injury
June 1, 2026
Minaal Ahmed Malik, Michele Halasa, Jack Chia et al.
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is widely used in trauma and emergency medicine for its rapid analgesic and sedative properties. While its efficacy in acute pain management is well established, concerns persist regarding its long-term psychological effects, particularly its potential role in the development of posttraumatic stress disorder (PTSD). Some studies...
Neuropsychopharmacology
June 1, 2026
Ted Obi, Kerry J. Ressler
Post-traumatic stress disorder (PTSD) remains one of psychiatry's most challenging disorders, common, disabling, and biologically complex. Despite decades of research, only sertraline and paroxetine are FDA-approved, both with modest efficacy. Even first-line trauma-focused psychotherapies leave up to half of patients with persistent symptoms. However, advances in neurobiology are reframing...
Journal of Traumatic Stress
June 1, 2026
Kadek Suhardita, Veno Dwi Krisnanda, Rikas Saputra et al.
In this commentary on Morland et al. (2026)'s recent State of the Science article on 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder (PTSD), we aim to emphasize both MDMA's therapeutic promise and its unresolved scientific challenges. Although recent trials on MDMA-assisted interventions have reported encouraging reductions in PTSD symptoms, the...